Viridian Therapeutics’ (VRDN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDNFree Report) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $34.00 price target on the stock.

Separately, Needham & Company LLC restated a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

View Our Latest Analysis on Viridian Therapeutics

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $13.50 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81. The firm’s 50 day simple moving average is $14.24 and its 200-day simple moving average is $18.27. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDNGet Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank boosted its stake in Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Viridian Therapeutics by 2.9% in the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company’s stock worth $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC lifted its stake in shares of Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock worth $410,000 after buying an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock worth $735,000 after acquiring an additional 1,106 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter valued at about $26,000.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

Recommended Stories

Analyst Recommendations for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.